Last10K.com

Zymeworks Inc. (ZYME) SEC Filing 10-Q Quarterly report for the period ending Monday, September 30, 2019

Zymeworks Inc.

CIK: 1403752 Ticker: ZYME

Exhibit 99.1

 

LOGO

Zymeworks Reports 2019 Second Quarter Financial Results

Vancouver, Canada (August 2, 2019) – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the second quarter ended June 30, 2019.

“We had a notable second quarter that included significant activity from our pharmaceutical partners and was highlighted by a successful financing,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “We are well capitalized to accelerate and expand the clinical development of both ZW25 and ZW49 and plan to provide updates in the near-term beginning with ZW25 single agent and chemo combination data this fall.”

Second Quarter 2019 Business Highlights and Recent Developments

 

   

Raised Over $200 Million in Upsized Public Offering

Zymeworks completed a public offering of 7,013,892 common shares (including the exercise in full of the underwriters’ over-allotment to purchase 1,458,336 additional common shares) and, in lieu of common shares, to a certain investor, pre-funded warrants to purchase up to 4,166,690 common shares, for aggregate gross proceeds of US$201.3 million.

 

   

First ZymeLink Platform Deal and Progress from Existing Partners

We granted Iconic Therapeutics a license to the ZymeLink Antibody Drug Conjugate (ADC) platform for its ICON-2 Tissue Factor ADC, marking our first collaboration leveraging the ZymeLink platform and our third technology platform licensed to a collaborator. In addition, we received milestone payments from Daiichi Sankyo, Merck, and Celgene as a result of advancements they made with their Azymetric bispecifics towards the clinic. Furthermore, GSK broadened its Azymetric platform license resulting in increased potential milestone payments and royalties to Zymeworks.

 

   

Received Fast Track Designation to Expedite ZW25’s Development

The FDA granted ZW25 Fast Track designation for frontline treatment of patients with advanced HER2-overexpressing gastroesophageal adenocarcinoma, an area of significant unmet medical need. Zymeworks is currently enrolling patients in a frontline Phase 2 clinical trial in combination with standard of care chemotherapy with plans to initiate a registrational trial in 2020.

 

   

Expanded Board of Directors Increases Commercial Expertise

As Zymeworks advances into late-stage clinical development, we added Dr. Sue Mahony and Troy Cox to our Board, two pharmaceutical executives with extensive global strategic development and therapeutic commercialization experience.


The following information was filed by Zymeworks Inc. (ZYME) on Friday, August 2, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Zymeworks Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Zymeworks Inc..

Continue

Assess how Zymeworks Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Zymeworks Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Changes In Shareholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Loss And Comprehensive Loss
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Intangible Assets And Goodwill - Additional Information (Detail)
Intangible Assets And Goodwill - Summary Of Carrying Value Of Ipr&Amp;D, Net Of Impairment (Detail)
Ipr&Amp;D And Goodwill
Ipr&Amp;D And Goodwill (Tables)
Leases
Leases (Tables)
Leases - Additional Information (Detail)
Leases - Schedule Of Balance Sheet Classification Of Lease Liabilities (Detail)
Leases - Schedule Of Maturities Of Finance Lease Liabilities (Detail)
Leases - Schedule Of Maturities Of Operating Lease Liabilities (Detail)
Liabilities
Liabilities (Tables)
Liabilities - Schedule Of Accounts Payable And Accrued Expenses (Detail)
Liabilities - Schedule Of Other Current Liabilities (Detail)
Liabilities - Schedule Of Other Long-Term Liabilities (Detail)
Nature Of Operations
Nature Of Operations - Additional Information (Detail)
Recent Accounting Pronouncement - Impact Of The Adoption Of Topic 842 On Balance Sheet (Detail)
Recent Accounting Pronouncements
Recent Accounting Pronouncements (Tables)
Recent Accounting Pronouncements - The Impact Of The Adoption Of Topic 842 On The Accompanying Condensed Consolidated Statements Of Operations (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity (Tables)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Additional Information (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Estimated Fair Value Of Stock Options Assumptions (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Schedule Of Stock-Based Compensation Expense For Equity Classified Instruments (Detail)
Redeemable Convertible Class A Preferred Shares, And Shareholders' Equity - Summary Of Stock Options Granted (Detail)
Research, Collaboration And Licensing Agreements
Research, Collaboration And Licensing Agreements (Tables)
Research, Collaboration And Licensing Agreements - Additional Information - Beigene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Celgene (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Gsk Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Iconic (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Janssen (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Leo (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Lilly Two (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Merck (Detail)
Research, Collaboration And Licensing Agreements - Additional Information - Strategic Partnership Revenue (Detail)
Research, Collaboration And Licensing Agreements - Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions (Detail)
Short-Term Investments
Short-Term Investments - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Changes In Fair Value Of Liability Classified Stock Options (Detail)
Summary Of Significant Accounting Policies - Schedule Of Financial Liabilities Measured At Fair Value On A Recurring Basis (Detail)
Summary Of Significant Accounting Policies - Summary Of Calculation Of Diluted Loss Per Share (Detail)
Summary Of Significant Accounting Policies - Summary Of Changes In Fair Value Of The Company's Liability For Contingent Consideration (Detail)

Material Contracts, Statements, Certifications & more

Zymeworks Inc. provided additional information to their SEC Filing as exhibits

Ticker: ZYME
CIK: 1403752
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-19-284726
Submitted to the SEC: Tue Nov 05 2019 4:17:17 PM EST
Accepted by the SEC: Tue Nov 05 2019
Period: Monday, September 30, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/zyme/0001193125-19-284726.htm